304 completed, 266 unknown, 75 recruiting, 34 active not recruiting. 332 Phase 1, 299 Phase 2, 147 Phase 3, 11 Not applicable, 9 Phase 4.
Follow Jiangsu HengRui Medicine Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorectal Cancer Expressing HER2 Trastuzumab Rezetecan (SHR-A1811) injection; high dose, Trastuzumab Rezetecan (SHR-A1811) injection; low dose - Advanced Colorectal Cancer Expressing HER2 | Phase 2 | Not yet recruiting | Jiangsu HengRui Medicine Co., Ltd. | 48 | 2026-11-01 | 2026-09-01 |
| FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy. FH-006, Paclitaxel, Docetaxel, Irinotecan - Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy | Phase 3 | Not yet recruiting | Jiangsu HengRui Medicine Co., Ltd. | 480 | 2026-10-10 | 2026-08-27 |
| Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation and Bolus Maintenance in Adults HRS-9190, Rocuronium - Neuromuscular Blockade | Phase 3 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 320 | 2026-09-02 | 2026-09-22 |
| An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors HRS-7172 + AG + SHR-1316, HRS-7172 + AG + SHR-1316;, HRS-7172 + AG; - Pancreatic Cancer | Phase 1 / Phase 2 | Not yet recruiting | Jiangsu HengRui Medicine Co., Ltd. | 140 | 2026-09-01 | 2026-09-08 |
| A Trial of HRS-7085 Tablets in Patients With Moderate to Severe Active Ulcerative Colitis HRS-7085 tablets, Placebo - Moderate to Severe Ulcerative Colitis | Phase 1 | Not yet recruiting | Jiangsu HengRui Medicine Co., Ltd. | 8 | 2026-08-01 | 2026-08-12 |
| Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM SCRT, Retlirafusp alfa Injection, Bevacizumab - CRC (Colorectal Cancer) | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 60 | 2026-07-30 | 2026-09-22 |
| A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer HRS-7525 tablets - Prostate Cancer | Phase 1 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 320 | 2026-07-30 | 2026-09-24 |
| A Study to Estimate Effect of Formulation and Food on Relative Bioavailability of HRS-6209 in Healthy Participants HRS-6209 Capsule (old formulation), HRS-6209 Capsule (new formulation) - Breast Cancer | Phase 1 | Active not recruiting | Jiangsu HengRui Medicine Co., Ltd. | 21 | 2026-06-08 | 2026-08-25 |
| Phase I Study of HRS-3005 in B-cell Malignancies HRS-3005 - B-cell Malignancy | Phase 1 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 190 | 2026-06-03 | 2026-09-09 |
| Adebrelimab Combined With Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Carcinoma • Adebrelimab and nab-paclitaxel, carboplatin in Combination With radiotherapy - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 37 | 2026-05-22 | 2026-05-19 |
| A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer Trastuzumab Rezetecan for Injection, Trastuzumab Deruxtecan for Injection - Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer | Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 150 | 2026-04-28 | 2026-05-11 |
| A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT) Hetrombopag Olamine, Hetrombopag Olamine; Hetrombopag Olamine Placebo - Patients With Chemotherapy-Induced Thrombocytopenia | Phase 3 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 150 | 2026-04-16 | 2026-10-01 |
| A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic Agents SHR-3167 Injection, SHR-3167 Injection Placebo - Diabetes Mellitus, Type 2 | Phase 2 | Active not recruiting | Jiangsu HengRui Medicine Co., Ltd. | 102 | 2026-04-11 | 2026-06-04 |
| Study on the Mass Balance of [14C]HRS-9190 for Injection in Healthy Participants [14C] HRS-9190 - Healthy Adult Male | Phase 1 | Active not recruiting | Jiangsu HengRui Medicine Co., Ltd. | 6 | 2026-04-11 | 2026-04-24 |
| Safety and Efficacy of HRS-9190 Compared to Cisatracurium for Continuous Intravenous Infusion in Adults HRS-9190; under Inhalational Anesthesia, HRS-9190; under Intravenous Anesthesia, Cisatracurium (under Inhalational Anesthesia). - Neuromuscular Blockade | Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 67 | 2026-04-10 | 2026-09-08 |
| A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer SHR-4394, Rezvilutamide, HRS-5041 Tablets - Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 100 | 2026-04-08 | 2026-04-21 |
| A Clinical Study Comparing the Relative Bioavailability and Safety of SHR-3167 Injection SHR-3167 Injection - Diabetes Mellitus | Phase 1 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 60 | 2026-04-02 | 2026-04-29 |
| A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects HRS-8364 Tablet - Solid Tumor | Phase 1 / Phase 2 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 282 | 2026-03-19 | 2026-04-03 |
| SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy SHR-1701+ liposomal irinotecan (II) - ESCC | Phase 2 | Not yet recruiting | Zhigang Li | 33 | 2026-03-15 | 2026-04-13 |
| A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors SHR-1049 Injection - Advanced Solid Tumor | Phase 1 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 200 | 2026-03-12 | 2026-04-16 |
Showing 20 of 742. Sign in to see all of them.
Breast Neoplasms (50) · Diabetes Mellitus, Type 2 (45) · Carcinoma, Non-Small-Cell Lung (21) · Stomach Neoplasms (20) · Neoplasms (17) · Colorectal Neoplasms (14) · Prostatic Neoplasms (14) · Carcinoma, Hepatocellular (13) · Ovarian Neoplasms (12) · Hyperuricemia (11) · Lung Neoplasms (11) · Arthritis, Rheumatoid (9) · Esophageal Squamous Cell Carcinoma (9) · Pain (9) · Pancreatic Neoplasms (9)
apatinib (97) · camrelizumab (93) · pyrotinib (35) · fluzoparib (26) · famitinib (25) · Docetaxel (24) · Injections (23) · Cisplatin (17) · Carboplatin (16) · Paclitaxel (15) · ruzinurad (14) · Capecitabine (13) · henagliflozin (13) · ivarmacitinib (13) · 130-nm albumin-bound paclitaxel (12)
China (655) · United States (10) · Australia (8) · South Korea (6) · Poland (5) · Spain (4) · Taiwan (4) · Belgium (3) · France (3) · Italy (3) · Russia (3) · Turkey (Türkiye) (3) · Bulgaria (2) · Czechia (2) · Germany (2)
Changyu Pan, M.D. (4) · Dingwei Ye, M.D. (3) · Qing Yang, MD (3) · Caigang Liu, MD (2) · Chunde Bao (2) · Feng Wang (2) · Huiqiang Huang, professor (2) · Jianjun Zou, MD, PhD (2) · Jin Li, MD (2) · Jinwan Wang, M.D (2) · Li Zhang, MD (2) · Lin Shen, MD (2) · RuiHua Xu, MD, PhD (2) · Ruihua Xu, M.D (2) · Shukui Qin, MD (2)
PMID 40587053, PMID 41773934, PMID 41196282, PMID 41528248, PMID 24292957, PMID 30213452, PMID 32178858, PMID 32898333, PMID 36135045, PMID 36803645, PMID 36852452, PMID 37409613, PMID 39024777, PMID 16466610, PMID 20923544, PMID 24939214, PMID 25376790, PMID 26755520, PMID 27602761, PMID 29273089, PMID 30510509, PMID 30971301, PMID 31138588, PMID 31261514, PMID 31401903, PMID 31420358, PMID 32112738, PMID 32218807, PMID 32376724, PMID 32416073, PMID 32614698, PMID 32865293, PMID 33087333, PMID 33109386, PMID 33166719, PMID 33172881, PMID 33323401, PMID 33347829, PMID 33383486, PMID 33420642, PMID 33581774, PMID 33632264, PMID 33693494, PMID 33741732, PMID 33766817, PMID 33845905, PMID 33971141, PMID 34174189, PMID 34309846, PMID 34519801